Page last updated: 2024-08-23

razoxane and Carcinoma, Lewis Lung

razoxane has been researched along with Carcinoma, Lewis Lung in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gershanovich, ML1
Ding, J; Lu, DY; Xu, B1
Ding, J; Huang, M; Lu, DY; Xu, B; Xu, CH; Zhu, H1

Other Studies

3 other study(ies) available for razoxane and Carcinoma, Lewis Lung

ArticleYear
[Cardioxan: prevention of anthracycline-related cardiotoxicity].
    Voprosy onkologii, 2004, Volume: 50, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cardiotonic Agents; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Neoplasms; Neoplasms, Experimental; Razoxane; Time Factors

2004
Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo.
    BMC pharmacology, 2004, Dec-24, Volume: 4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; China; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Razoxane; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2004
Medicinal chemistry of probimane and MST-16: comparison of anticancer effects between bisdioxopiperazines.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2006, Volume: 2, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mice; Mice, Nude; Molecular Structure; Piperazines; Razoxane; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays

2006